```html

Urinogenital Schistosomiasis – A Comprehensive Medical Guide

Overview

Urinogenital schistosomiasis (also called urinary schistosomiasis or bilharzia) is a parasitic disease caused by the blood‑fluke Schistosoma haematobium. The parasite lives in the small veins surrounding the bladder and ureters. When eggs are released into the urinary tract they cause inflammation, bleeding, and long‑term damage.

The disease is endemic in many parts of sub‑Saharan Africa, the Middle East, and, to a lesser extent, parts of South America and Asia. According to the World Health Organization, >100 million people are infected with any form of schistosomiasis, and ~15 million have the urinary form alone, representing roughly 15 % of all cases worldwide.<sup>WHO, 2023</sup>

It primarily affects children and adolescents who regularly swim or bathe in contaminated freshwater, but adults who work in agriculture, fishing, or irrigation can also be infected.

Symptoms

Symptoms may appear weeks after the initial skin penetration and can be intermittent. The clinical picture varies with infection intensity and duration.

Acute (Katayama) phase – weeks to months after exposure

• Fever, chills, and malaise – a flu‑like syndrome.
• Headache and muscle aches – systemic inflammation.
• Abdominal pain – especially suprapubic.
• Cough and wheezing – due to migration of larvae through lungs.
• Eosinophilia – high eosinophil count on blood work.

Chronic phase – months to years

• Hematuria (blood in urine) – often painless and most common sign.
• Terminal‑stream hematuria – blood appears at the end of urination.
• Frequent urination and urgency.
• Painful urination (dysuria).
• Pelvic or flank pain due to bladder wall fibrosis.
• Suprapubic mass in severe cases (bladder wall thickening).
• Female genital lesions – itching, discharge, or ulceration when eggs migrate to the cervix, vagina, or vulva.
• Male infertility – obstruction or inflammation of the seminal vesicles and vas deferens.
• Kidney involvement – proteinuria, occasional hematuria from upper urinary tract.

Causes and Risk Factors

Cause: Infection occurs when free‑swimming larval forms (cercariae) released from freshwater snails of the genus Bulinus penetrate human skin. Once inside, they develop into adult worms that reside in the vesical and pelvic venous plexus, laying eggs that migrate into the bladder lumen.

Key Risk Factors

• Geographic exposure – living in or traveling to endemic regions with known Schistosoma haematobium transmission.
• Water contact activities – swimming, wading, washing clothes, or fishing in freshwater bodies that may harbor infected snails.
• Occupational exposure – irrigation, rice farming, or construction near stagnant water.
• Age – children 5–15 years have the highest incidence because of recreational water exposure.
• Poor sanitation – lack of latrines leads to contamination of water sources with human waste that sustains the snail cycle.
• Immunocompromised state – HIV infection can increase susceptibility and severity.

Diagnosis

Diagnosis combines clinical suspicion with laboratory and imaging studies.

Laboratory Tests

• Urine microscopy – the gold standard. A fresh mid‑day urine sample (10 ml) is filtered; the presence of S. haematobium eggs confirms infection. Sensitivity improves with three consecutive samples collected on consecutive days.<sup>CDC, 2022</sup>
• Urine antigen tests (CCA/CAA) – rapid dipsticks detecting circulating cathodic/antigenic antigen; useful in low‑intensity infections.
• Serology (ELISA) – detects antibodies; helpful for travelers but cannot distinguish active from past infection.
• Complete blood count – often shows eosinophilia (>500 cells/µL).

Imaging

• Ultrasound – evaluates bladder wall thickness, ureteral dilation, and kidney changes. The WHO grading system for urinary schistosomiasis relies on ultrasound findings.
• Cystoscopy – visualizes “sandy patches” or granulomas; reserved for severe or refractory cases.

Biopsy (rare)

In atypical presentations, a small bladder biopsy can demonstrate egg‑induced granulomas.

Treatment Options

Effective therapy is available and inexpensive.

First‑line Antiparasitic Medication

• Praziquantel – 40 mg/kg as a single dose (or 20 mg/kg twice a day 4–6 hours apart). It increases the parasite’s membrane permeability, causing paralysis and death.<sup>Mayo Clinic, 2023</sup>
• For children, the dose is weight‑based; pediatric formulations are available.
• Re‑treatment after 4–6 weeks is recommended if eggs are still present in urine.

Adjunctive Measures

• Anti‑inflammatory therapy (e.g., NSAIDs) for acute pain or dysuria.
• Antibiotics only if a secondary bacterial urinary tract infection is documented.
• Management of complications such as bladder cancer (cystectomy) or ureteral obstruction (stenting) when indicated.

Lifestyle & Supportive Care

• Increase fluid intake to dilute urine and reduce irritation.
• Avoid bladder irritants (caffeine, alcohol, spicy foods) while inflammation resolves.
• Regular follow‑up urine microscopy at 3, 6, and 12 months post‑treatment to confirm cure.

Living with Urinogenital Schistosomiasis

Even after successful treatment, long‑term monitoring is essential.

Daily Management Tips

• Hydration – Aim for ≥2 L of water per day unless contraindicated.
• Bladder training – Schedule regular bathroom breaks; avoid holding urine for prolonged periods.
• Hygiene – Thorough perineal cleaning after toileting; use mild, unscented soaps.
• Monitor urine – Keep a diary of any blood, pain, or changes in frequency; report persistent hematuria.
• Sexual health – Use barrier protection; genital lesions increase susceptibility to HIV and other STIs.
• Vaccinations – Ensure up‑to‑date hepatitis B and HPV vaccinations, as chronic inflammation can synergize with viral oncogenesis.

Follow‑up Schedule

1. 3 months: repeat urine microscopy and ultrasound.
2. 6 months: clinical review; repeat labs if symptoms persist.
3. Annually for 5 years: urine microscopy and bladder ultrasound to screen for early neoplastic changes, especially in high‑risk regions.

Prevention

Prevention focuses on breaking the parasite’s life cycle and reducing exposure.

Individual Measures

• Avoid contact with freshwater in endemic areas; use boiled or filtered water for bathing.
• Protective footwear – wear waterproof shoes or boots when wading.
• Safe water practices – drink only treated water; avoid swimming in lakes, ponds, or slow‑moving rivers known to harbor snails.

Community & Public Health Strategies

• Mass drug administration (MDA) – WHO recommends annual praziquantel distribution to school‑age children in high‑prevalence zones.<sup>WHO, 2022</sup>
• Snail control – environmental modification (draining stagnant water), molluscicides, and introducing competitor fish species.
• Improved sanitation – building latrines to prevent contamination of water bodies with human waste.
• Health education – community campaigns teaching about disease transmission and safe water use.

Complications

If left untreated, chronic urinogenital schistosomiasis can cause serious morbidity.

• Bladder fibrosis & contracture – leads to obstructive uropathy, hydronephrosis, and renal failure.
• Squamous cell carcinoma of the bladder – risk is 3–4‑fold higher in endemic areas; it accounts for up to 30 % of bladder cancers in Africa.<sup>Cleveland Clinic</sup>
• Male infertility – due to obstruction of the seminal vesicles or ejaculatory ducts.
• Female genital schistosomiasis (FGS) – associated with increased susceptibility to HIV, HPV, and cervical cancer.
• Kidney damage – chronic hematuria can cause iron‑deficiency anemia and progressive renal insufficiency.
• Recurrent urinary tract infections – eggs and granulomas provide a nidus for bacterial overgrowth.

When to Seek Emergency Care

---

For personalized advice, always consult a healthcare professional familiar with tropical diseases. Reliable information can also be found at the CDC, WHO, and the Mayo Clinic.

```